A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
about
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseNail Psoriasis: A Review of Treatment OptionsA Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisSelective Phosphodiesterase Inhibitors for Psoriasis: Focus on ApremilastMucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapyCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisMethotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trialsSafety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.Rationale and early clinical data on IL-17 blockade in psoriasis.Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions.Systemic methotrexate therapy for psoriasis: past, present and future.[Nail psoriasis--an ignored disorder. Pathogenesis, diagnosis and therapy].Treatment of nail psoriasis: common concepts and new trendsPreclinical development of AMG 139, a human antibody specifically targeting IL-23Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.Briakinumab for treatment of Crohn's disease: results of a randomized trialSafety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.The Role of IL-17 and Th17 Lymphocytes in Autoimmune DiseasesAssociation of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to dateUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.IL-12 protects from psoriasiform skin inflammationImplementing treatment goals for successful long-term management of psoriasis.Current investigational drugs in psoriasis.Current and emerging systemic treatment strategies for psoriasis.Targeting the Th17 pathway in psoriasis.A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.Biological therapies for psoriasis.IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.An updated survey for the 2007-2013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship.Systemic methotrexate for the treatment of psoriasis.Cutaneous immunology: basics and new concepts.Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Safety profile of methotrexate in inflammatory bowel disease.Immunotargeting in the management of psoriasis.Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.The role of IL 23 in the treatment of psoriasis.
P2860
Q24188040-49A4FDFA-FE36-49FA-A281-4F3CDB24186CQ26753038-1C003DDC-6FE8-4EAC-A7AA-1F08788A1B4FQ26771682-762ECD12-0771-41C5-B792-AC47587FD31CQ26781755-8BB1EBC8-99C2-443A-B9B2-177D31D5AA0EQ27010562-F1D37B95-EAD0-4702-A989-3CF9629D0E6EQ27025692-055229A6-60C0-4D5B-901E-3906E4CBFE39Q27693878-AC071FB7-868D-4F2E-BEE1-CEA1093C6419Q28085725-3305BEA7-B796-4D5A-9DD7-F25705541CE8Q30577671-6CB53385-8C08-422A-8382-094737F39C5BQ30658185-16BA408E-5AE0-4F3D-BC1B-6474E53D7CA5Q34166896-A2D1B5F0-10C0-43C7-AAAA-AD293E112CA1Q34294189-D8EC990D-A446-4290-8349-9BC87FC6FE07Q34356265-AF6D5111-90BD-42B4-ACE3-F16E64E76252Q34636311-862910FB-2309-4610-9BF0-B68EDEBF31CDQ34769284-203FEB47-8D55-491A-B9BA-80F56F7C2B72Q34795742-E1949A17-39C1-4895-8F58-504B04F7F306Q35263519-E4D4F942-7859-4C7D-B86A-29EFA3CD95E4Q35670615-CF165E87-F43A-4C2D-A0C7-1DBF491D04B2Q36014642-AB3AECAC-7623-4C3E-9747-FFC8E25DD693Q36203845-EDAE30A9-3B9D-448C-BAB5-22D2A691929FQ36249305-55636A14-9576-459C-847A-0C690168195BQ36643600-CCDE5991-C6ED-4CBE-A7A1-0CF20C86F3C8Q37258726-C0BC5D4C-DFA7-4018-BE5F-42A2709623D8Q37465195-9338FF66-CE48-45CA-8745-8570EE45F060Q37987269-0A88D35D-8C87-4A9B-8E37-A5C73BE7F659Q37991748-213D5E6F-37A9-43B0-9F9E-EB4DF204B4AEQ38039491-3DFD2F18-6E8E-4E1F-A8EF-285D3BFA1D35Q38042048-C8AABA02-547C-4F07-904C-463D5CC221F5Q38084325-87A43DB5-A167-43FC-AA65-C0736832D9C6Q38155648-CAEAA9B1-11FD-4EE6-8CEC-644541702318Q38255855-EA698F6A-BB8F-420F-A551-5080C2A90603Q38375060-37F4924C-7E09-4692-8DC1-A4E917BFFB1EQ38380882-6863A96F-AEF6-4BFB-8A6D-78E6FAF08135Q38632000-2D969338-8E42-4334-B123-41F50C1F5AEAQ38632657-CF441E64-2377-4881-B257-A5AAE7133755Q38879975-E7122F0A-95D5-418E-9B92-EF1835895C63Q38909929-98D08D57-7EC7-4C5F-BE1A-5763463EDAB5Q38912240-93E81F70-64EE-44CF-8948-D94E8FB5188AQ38969036-F1620B52-58E5-4387-BEF9-0BBF61177625Q38976762-B61C08F3-7DF1-46E8-B281-2AD61228D55A
P2860
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
@en
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
@nl
type
label
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
@en
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
@nl
prefLabel
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
@en
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
@nl
P2093
P356
P1476
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis
@en
P2093
Jean-Paul Ortonne
Joaquin M Valdes
Kristian Reich
Kristina Unnebrink
Martin Kaul
Richard G Langley
P304
P356
10.1056/NEJMOA1010858
P407
P50
P577
2011-10-01T00:00:00Z